Compare ICU & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICU | HKPD |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 10.6M |
| IPO Year | N/A | 2025 |
| Metric | ICU | HKPD |
|---|---|---|
| Price | $2.26 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 119.4K | 50.7K |
| Earning Date | 03-26-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $881,000.00 | ★ $20,313,818.00 |
| Revenue This Year | $1,043.70 | N/A |
| Revenue Next Year | $54.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1195.59 | 21.72 |
| 52 Week Low | $2.20 | $0.66 |
| 52 Week High | $25.70 | $2.76 |
| Indicator | ICU | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 50.83 |
| Support Level | $2.31 | $0.75 |
| Resistance Level | $2.74 | $0.89 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 21.57 | 65.82 |
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.